Studies Addressing Rare Neurodegenerative Diseases including ALS
Forecasted Federal grant Posted
- Opportunity number
- FOR-FD-25-006
- Agency
-
Food and Drug Administration
Department of Health and Human Services
- Applications expected due
- Not on record
- Award size
- Not on record
Opportunity facts
- Assistance listings
- Funding instrument
- Grant
- Categories
-
- Consumer Protection
- Agriculture
- Food and Nutrition
- Eligible applicants
-
- Unrestricted
- State Governments
- Independent School Districts
- Higher Education Inst. (Private)
- City/Township Governments
- 501(c)(3) Nonprofits
- Public or Indian Housing Auth.
- Non-501(c)(3) Nonprofits
- Tribal Organizations (Not Federally Recognized)
- Higher Education Inst. (Public)
- County Governments
- Small Businesses
- Special District Governments
- For Profit Organizations
- Tribal Governments (Federally Recognized)
- Points of contact
-
- Terrin Brown terrin.brown@fda.hhs.gov (240) 402-7610
Opportunity details come from Grants.gov. Updated .
About this opportunity
The Food and Drug Administration is soliciting applications to support studies advancing medical product development of interventions intended to prevent, diagnose, mitigate, treat, or cure amyotrophic lateral sclerosis and other rare neurodegenerative diseases in adults and children. This is a forecast announcement with no specific application deadline stated in the source material. The opportunity is unrestricted and open to state governments, higher education institutions (public and private), 501(c)(3) and non-501(c)(3) nonprofits, city and county governments, small businesses, for-profit organizations, tribal governments (federally recognized and non-federally recognized), special district governments, independent school districts, and public or Indian housing authorities. No cost share requirement or award ceiling is specified in the source material. FDA's stated intent is to address critical knowledge gaps, exert significant impact on rare neurodegenerative diseases, and inform current or future product development through the funded studies. The program operates under CFDA 93.103 (Food and Drug Administration Research), which has sustained grant-making activity across 45 years with recent award rates of 90 to 167 grants per year. The program portfolio reflects a mix of funding instruments, predominantly cooperative agreements (58% of awards) and project grants (40%). Recent FDA research awards in related areas have ranged from $50 thousand to $6.8 million, with state laboratory cooperative agreements ranging from $250 thousand to $2.4 million. Non-federal cost-share has historically contributed $220 million across the program's 3,008 total grants.
Forecast synopsis
The purpose of this funding opportunity announcement (FOA) is to support studies that advance medical product development of interventions intended to prevent, diagnose, mitigate, treat, or cure ALS and other rare neurodegenerative diseases in adults and children. Through the support of these studies, FDA expects to address critical knowledge gaps, exert a significant impact on rare neurodegenerative diseases, and to inform current or future product development.
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar grant opportunities
- Ask GovTribe AI about this opportunity